| 18.09 16:26 | dpa-AFX: BioMarin's CANOPY Trial Shows Positive Data About Voxzogo In Children With Achondroplasia |
| 18.09 14:05 | dpa-AFX: *BIOMARIN :DATA SHOWS MEANINGFUL IMPROVEMENTS BEYOND HEIGHT IN CHILDREN WITH ACHONDROPLASIA TREATED WITH VOXZOGO |
| 21.08 14:32 | dpa-AFX: *BIOMARIN PHARMA APPOINTS GREG FRIBERG AS EVP, CHIEF RESEARCH & DEVELOPMENT OFFICER |
| 05.08 22:10 | dpa-AFX: Biomarin Pharmaceutical Inc. Q2 Profit Increases, Beats Estimates |
| 05.08 22:05 | dpa-AFX: *BIOMARIN Q2 EPS $0.55 VS. $0.29 YEAR AGO |
| 05.08 22:05 | dpa-AFX: *BIOMARIN Q2 REVENUES $712.03 MLN VS. $595.28 MLN LAST YEAR |
| 05.08 22:05 | dpa-AFX: *BIOMARIN Q2 NET INCOME $107.17 MLN VS. $56.04 MLN PRIOR YEAR |
| 05.08 21:01 | dpa-AFX: Biomarin Pharma Q2 24 Earnings Conference Call At 4:30 PM ET |
| 25.07 03:50 | dpa-AFX: FDA Approves BioMarin Pharma's BRINEURA For Children Under 3 Years With CLN2 Disease |
| 17.06 15:08 | dpa-AFX: BioMarin: Investigator-Led 5-yr Study Shows VOXZOGO Significantly Increases Bone Length |
| 17.06 14:34 | dpa-AFX: *BIOMARIN STUDY: VOXZOGO BOOSTS BONE LENGTH, MAINTAINS STRENGTH IN ACHONDROPLASIA KIDS OVER 5 YEARS |
| 07.06 15:19 | dpa-AFX: BioMarin: 4-Yr Data From Phase 3 Hemophilia Gene Therapy Study Shows Safety, Efficacy Of ROCTAVIAN |
| 07.06 15:05 | dpa-AFX: *BIOMARIN: STUDY ON ROCTAVIAN SHOWS LONG-TERM BLEED CONTROL & FACTOR VIII EXPRESSION |
| 24.04 22:07 | dpa-AFX: Biomarin Pharmaceutical Inc. Q1 Profit Increases, beats estimates |
| 24.04 22:05 | dpa-AFX: *BIOMARIN Q1 NET INCOME $88.7 MLN VS. $50.9 MLN PRIOR YEAR |
| 24.04 22:05 | dpa-AFX: *BIOMARIN Q1 EPS $0.46 VS .$0.27 YEAR AGO |
| 24.04 22:05 | dpa-AFX: *BIOMARIN Q1 REVENUES $648.8 MLN VS. $596.4 MLN LAST YEAR |
| 24.04 21:03 | dpa-AFX: Biomarin Pharma Q1 24 Earnings Conference Call At 4:30 PM ET |
| 22.02 22:06 | dpa-AFX: Biomarin Pharmaceutical Inc. Q4 Earnings Summary |
| 22.02 22:06 | dpa-AFX: *BIOMARIN Q4 EPS $0.11 VS. BREAKEVEN YEAR AGO |
|
|
